ÂÜÀòÂÒÂ×

Dr. David Bonita is a Private Equity Partner at OrbiMed, where he serves on the boards of Loxo Oncology, Kyn Therapeutics, Clementia Pharmaceuticals, Tricida, Prelude Therapeutics, ViewRay, SI Bone and Keystone Heart. He previously served on the boards of Enobia Pharma, CardiAQ and Ambit Bioscience. Prior to joining OrbiMed, Dr. Bonita worked in the healthcare investment banking groups of Morgan Stanley and UBS. He has published several scientific articles in peer-reviewed journals based on research performed at the Harvard Medical School. Dr. Bonita received his AB degree magna cum laude in Biological Sciences from Harvard University and his joint MD/MBA from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society.